Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial
To evaluated the safety and feasibility of fondaparinux in the percutaneous coronary intervention (PCI) setting and showed that fondaparinux was comparable to UFH for clinical safety and efficacy outcomes. These data contributed to further evaluation of fondaparinux in arterial thrombosis.
Randomized, multicenter, blinded, phase II, pilot trial
Primary Outcome: The composite of major and minor bleeding (total bleeding) events 48 hours after PCI. The principal efficacy measure was a composite of clinical outcomes, including death, MI, urgent revascularization, and bailout use of a GPIIb/IIIa antagonist.